Objective: To assess the efficiency of alternative monitoring services for people with ocular hypertension (OHT), a glaucoma risk factor.
INTRODUCTION
Avoiding sight loss is a public health priority [1] but decisions have to be made in terms of how best to manage eye care across competing demands. In the UK, about 24,000 people are newly registered with sight loss each year (blind and partial sight) with glaucoma being second to macular degeneration as the leading cause. [2, 3] Although ocular hypertension is the main and only modifiable risk factor for glaucoma [4, 5] organising a monitoring programme to monitor intraocular pressure (IOP) and detect early glaucoma has the potential to overburden health care and patients. Choices have to be made.
The UK National Institute for Health and Care Excellence (NICE) clinical guideline for glaucoma [6] recommends long-term monitoring of ocular hypertension in specialist (health care professional accredited in glaucoma) led service either in secondary care (consultant led hospital eye service) or primary care (community optometry) depending on local commissioning arrangements. Thresholds for initiating ocular hypotensive treatment are defined proportionate to glaucoma risk with stratification based upon the findings of a Markov economic model. [6] Recommended monitoring intervals were informed by a budget impact analysis and expert opinion. However, concerns were subsequently raised that glaucoma services are overburdened with monitoring low risk disease. [7] This study compares plausible alternative monitoring programmes for ocular hypertension (varying monitoring intervals, setting and treatment thresholds) to inform eye care policy in the UK. The study is part of a wider programme of work commissioned by the National Institute of Health Research, Health Technology Assessment programme to determine the optimum surveillance for people with ocular hypertension and is reported elsewhere in full. [8] 
METHODS
We developed a discrete event simulation model [8] Apart from the 'treat all' pathway, each simulated individual within the model had a predefined glaucoma risk, which was based on the natural history of open angle glaucoma estimated from the distribution of predictors in a European derived population. [11] The mean age of the simulated population cohort was 57 years, with lower and upper inter quartile range limits of 51 and 64
respectively, and mean IOP of 25 mmHg ranging from 21-36mmHg. The underlying distribution of IOP in the simulated cohort over time was estimated from predictions of a mixed linear regression model based on IOP data from an untreated ocular hypertension cohort and described in detail elsewhere. [8] The uncertainty due to measurement variability according to tonometer used was also included. [12] We populated the model with data from systematic reviews and statistical modelling estimates of the variability in IOP measurements and visual field indices [8] based on data from the placebo arms of two randomised controlled ocular hypertension treatment trials. [11, 13] Untreated. Variance based on assumption. [14] Time of progression from moderate to severe glaucoma 9 Normal (9, 2)
Untreated. Variance based on assumption. [14] Time of progression from severe glaucoma to visual impairment 10 Normal (10, 2)
Untreated. Variance based on assumption. [14] Treatment efficacy
Mean IOP reduction (%) Source

BB vs. no Treatment 12
Developed based on weighted mean differences in NICE guideline [6] PGA vs. BB 5
Developed based on weighted mean differences in NICE guideline [6] PGA + BB vs. PGA 1.5
Developed based on weighted mean differences in NICE guideline [6] Treatment effectiveness (risk of glaucoma or progressive glaucoma) ] * Probability distributions are used to simulate a hypothetical cohort of people with ocular hypertension; details are described in the text below. †Monocular visual field loss, mean deviation (MD in decibels (dB)) Mild glaucoma, 0.01 to -6.00dB; moderate glaucoma, -6.01 to -12.0 dB; severe glaucoma, -12.01 to -20.00 dB; visual impairment -20.01 dB to worse. [18] ‡ error term used in the model to reflect variability in IOP based on cohort data [8] § error term used in the model to reflect inter observer error in tonometry [8] and data from 255 people with glaucoma [18] valued using UK population tariffs. We assumed that the score for those with ocular hypertension was the same as for mild glaucoma. We addressed uncertainty by running one-way sensitivity analyses on a simulated cohort of 1000 individuals. Sensitivity analyses included changing the following parameters in the biennial pathways: 
Reduction in risk of progression from any medical treatment (hazard ratio)
C o n f i d e n t i
RESULTS
The baseline characteristics of the simulated individual characteristics are described in Table 4 . Over a 20-year time horizon the risk of converting to early glaucoma using the five monitoring strategies varied between 21-23%. The 'treat all' pathway (ocular hypotensive drops initiated irrespective of glaucoma risk, annual IOP monitoring in primary care with referral to secondary care if IOP treatment response was inadequate) was the least costly and least effective in terms of number of people progressing to glaucoma, table 4. NICE intensive monitoring was the most effective in avoiding conversion to and progression of glaucoma but the most costly pathway. Taking a broader perspective, by including quality of life, the differences in QALYS between any of the monitoring pathways are small as only a modest number of people in the cohort progress to any stage of glaucoma. Biennial monitoring in secondary care is more costly but provides more QALYS than a 'treat all' pathway. However the incremental cost-effectiveness ratio (ICER), in moving from the 'treat all' pathway to biennial monitoring in secondary care, of around £87,000 is much larger than the usual maximum threshold of willingness to pay (WTP) for a QALY adopted by NICE in considering implementation of new policies (£20-30,000 per QALY gained). [9] A summary of the findings of the sensitivity analyses is presented as on line supplementary material (Appendix 2). The results were not sensitive to varying the risk threshold for initiating surveillance (6-50%) but were sensitive to increasing the threshold for treatment. When the treatment threshold was increased to a 5-year glaucoma risk of 15% the biennial monitoring pathway (secondary care) dominated the 'treat-all' pathway (less costly and resulted in more QALYs). Sensitivity analyses around unit costs of treatment did not change the ICERs substantially. Varying the unit price of treatment with a prostaglandin analogue reduced the average costs for all pathways particularly those that involved more treatment ('treat all') but as expected no effect was observed on QALYS as only the unit costs of treatment changed.
The findings of the base case analysis were sensitive to varying unit costs for health care visits for a glaucoma-monitoring visit (including perimetry) and visits to measure IOP in response to treatment. If the unit cost of hospital visit was reduced from the base case value (£180) to £73 and an IOP only visit from £90 to £51, biennial monitoring in secondary care was cost effective compared with a 'treat-all' pathway, ICER £10,857 per QALY gained. Retaining the hospital glaucoma assessment at base case level (£180) but reducing the costs of an IOP visit, if the unit cost of an eye care visit was £50-55, biennial monitoring in secondary care was cost effective, ICER £11,410 per QALY gained.
The results were also sensitive to varying the estimated adherence to ocular hypotensive treatment.
When adherence decreased for a 'treat-all 'pathway the cost effectiveness of biennial monitoring 
DISCUSSION
We modelled less intensive pathways than recommended in the current NICE glaucoma guideline [6] to explore optimal treatment thresholds and monitoring intervals for people with ocular hypertension.
Additionally, we used findings from statistical models of cohort data to inform an individual's risk stratification and the frequency of monitoring in our biennial monitoring pathways. These data were not available when the NICE clinical guideline was developed. Although effective at reducing the incidence of glaucoma, based on this study's findings, pathways based on current NICE recommended pathways are unlikely to be cost-effective from a UK policy perspective compared with the alternative approaches we explored. Initiating treatment as soon as ocular hypertension is identified with minimal monitoring once the target IOP is reached is the least costly approach and compared with the alternative pathways modelled could be seen as the most cost-effective (balancing cost and QALYs gained). Alternatively, based on the sensitivity analyses, initiating treatment if the 5-year glaucoma risk was >10%, minimising the cost of repeat eye care visits and supporting patient adherence to treatment, with subsequent glaucoma tests every two years could be an efficient approach for surveillance of ocular hypertension. There are uncertainties regarding the optimal glaucoma risk threshold for initiating treatment, service costs, and long-term adherence to medication.
The impact of any treatment side effects may not be fully captured in QALY estimates.
These findings should be interpreted bearing in mind the limitations of the data available to populate the model. In particular, natural history data represented ocular hypertensive populations included in randomised controlled trials and are not necessarily generalisable to those with ocular hypertension presenting to routine eye care services.
We used a discrete event simulation model, which simulates the costs and consequences of individual patients, enabling disease modelling and event complexities that are difficult to model in simpler more commonly used modelling approaches such as decision tree or Markov models. In any modelling exercise there are uncertainties in model structure, i.e. are the care pathways modelled appropriate, parameter uncertainty regarding the data used and time horizon of the model? We used recommended best practice methods to ensure validity of the model. This included extensive validation and calibration exercises. As part of the model implementation process we verified, validated (to verify the model fits the empirical data) and calibrated the model where needed. We simulated individual characteristics for a population of 1000 people at the point where they enter into the model. The data were interpreted alongside data from the literature to judge face validity. [11] . In addition, we ran the [10, 19] We developed the care pathways using the NICE glaucoma guideline as a representation of current recommended practice for managing ocular hypertension. This may not reflect actual practice around the UK but was a standardised comparator. We developed two pathways capturing the extremes of the NICE recommended pathways, based on these extremes the cost-effectiveness of anything in between could be inferred. As there is limited capacity in hospital eye care services, we developed alternative pathways to test whether less intensive monitoring would be a cost-effective option for a national health service. These alternative monitoring scenarios were developed in consultation with ophthalmologists, nurses, patients and the public [8] and a recent economic evaluation in the Netherlands that suggested that a treating ocular hypertension irrespective of glaucoma risk was a cost-effective approach in a Dutch context. [20] As neither of the extreme scenarios based on NICE were cost-effective compared with minimal glaucoma monitoring it is unlikely that any other strategy consistent with NICE guidance would be cost-effective. However it should be noted that the original version of the model did not allow for people deemed at low risk of developing glaucoma (CCT>590micrometres and IOP<32mmHg) to be discharged after having a stable IOP for more than 3 years. We added this condition in a subsequent model development and the base case results reported in Table 5 remain robust. Discharged individuals move to yearly check-ups at a community optometrist and while the NICE informed strategies become, on average, less costly, they are not costeffective compared with the other modelled strategies.
We used data from systematic reviews of glaucoma risk prediction tools and statistical models determining the optimum frequency of monitoring IOP to detect true change from measurement noise to populate the model. For the statistical model we used serial measures of IOP and explored visual field data from the placebo group of randomised controlled treatment trials [11, 13] which may not be representative of variability in the general population. Repeat measures of visual fields were sparse in these trial data thus the model estimates were based solely on IOP data. It should be noted, however, that in the trial cohorts the visual fields (mean deviation) showed no true change over four years. [8] We characterised the risk of developing glaucoma using a glaucoma 5-year risk estimator [21] and applied this risk prediction model to the simulated cohort. This glaucoma risk model has good predictive utility for estimating the 5-year risk of open angle glaucoma in an external validation study. [19] It is available as an online tool and may be easier to use in clinical practice than risk stratification based on age, CCT and IOP as in the NICE guideline although this has not been evaluated as far as we are aware. In two of our 'new' pathways, ocular hypotensive treatment was Hypertension Treatment Study cohort where low glaucoma five-year risk was defined arbitrarily as <6%, moderate as 6-13% and high-risk as >13%. [22] We took a 20-year time horizon, which might not be sufficiently long to fully capture the impact on vision in a condition (i.e. glaucoma) that is slowly progressive for most people. We chose this horizon as extrapolating 5-year effectiveness data to even longer time horizons would be questionable. If we had taken a lifetime horizon more cases of visual impairment would have occurred, but given the time it takes to develop visual impairment, discounting would have reduced their impact on any differences between alternative pathways.
A similar evaluation was conducted in the Netherlands, investigating direct treatment initiation in ocular hypertension evaluated from a societal perspective with a lifetime horizon.
[20] Direct pressure lowering treatment was less costly and more effective than a strategy of delaying treatment until early signs of glaucoma are apparent. The uncertainty surrounding the model parameters did not affect the conclusions. In the Dutch model adherence to treatment was not taken into account as it was assumed that it was an implicit part of the treatment effectiveness estimates. However, these estimates were from selected trial populations where adherence may be greater than in clinical practice.. We explored varying adherence based on published estimates, [23] [24] [25] further data would reduce the uncertainty in our findings.
Findings were also sensitive to the costs of repeat visits to assess treatment responsiveness (IOP) but were not sensitive to medication costs. For community monitoring we used a cost of £20.70 based upon the NHS sight test tariff. Should this cost be too low, for example should additional charges be incurred for the use of additional tests, then a higher cost would make community monitoring even less cost-effective than the base case results indicate.
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